MedTrace Logo

Single Escalating Dose Study Of HSK7653 In Healthy Subjects

NCT05983289 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2023-08-09

No results posted yet for this study

Summary

To evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of single dose of HSK7653 tablets in healthy adult subjects, and to identify the metabolites of HSK7653 in healthy adult subjects

Conditions

  • T2DM (Type 2 Diabetes Mellitus)

Interventions

DRUG

HSK7653

HSK7653 tablets in six doses beginning at 5 mg and rising to 150 mg

DRUG

Placebo

Matching placebo tables in six doses beginning at 5 mg and rising to 150 mg

Sponsors & Collaborators

  • Haisco Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Hongzhong Liu · Peking Union Medical College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-05-08
Primary Completion
2019-07-03
Completion
2019-07-03

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05983289 on ClinicalTrials.gov